~~<i id='A1EEB76A06'><strike id='A1EEB76A06'><tt id='A1EEB76A06'><pre id='A1EEB76A06'></pre></tt></strike></i>~~

Home» focus» fashion

fashion

author：comprehensive 2025-09-30 05:30:11 Page View：336

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： CDC overhauls leadership of center that led response to Covid
Next article： As demand for Covid shots wanes, Moderna seeks its next success

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

EU fines Illumina $475 million over Grail acquisition

AdobeLONDON—TheEuropeanUniononWednesdayissuedanantitrustfineof$475milliontotheU.S.geneticsequencingg

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Where are patients getting their prescriptions for GLP

AdobeAsanewclassofdiabetesandobesitymedicationshassoaredinpopularity,sohavetheonlineoutletsbuilttoge